Abstract
The treatment of infections with immunostimulating drugs has been termed by us a “prohost” approach since the therapy is designed to increase host resistance rather than directly kill the pathogen. The origins of this approach go back into history to the use of Chinese traditional herbal medicines to strengthen the host (“stimulate the yin”). At the turn of the century Metchnikoff advocated stimulating the phagocytes to enhance host resistance. More recently, vaccine development has been employed to specifically prepare the host for pathogen challenge.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
J. W. Hadden, C. Lopez, R. J. O’Reilly and E. M. Hadden, Levamisole and inosiplex: Antiviral agents with immunopotentiating action, NY Acad. Sci. 284:139 (1976).
G. H. Werner, Immunopotentiating substances with antiviral activity, Phar. Ther. 6:235 (1979).
H. Friedman and S. Specter, Immunotherapy and immunoregulation, in: “Chemotherapy of Viral Infection,” P. E. Came and L. A. Caliguri, eds., Springer-Verlag, Berlin (1982).
J. W. Hadden, Immunostimulation therapy in the treatment of infectious diseases, in: “Immunotherapy and Viral Diseases,” J. W. Hadden, F. Sorice and J-L. Touraine, eds., EOS Sigma Tau, Rome (1985).
M. Lopez-Cepero, S. Specter, and J. W. Hadden, Implications for immunotherapy of viral infections, in: “Virus-Induced Immunosuppression,” S. Specter, M. Bendinelli and H. Friedman, eds., Plenum Press, New York (1989).
J. W. Hadden, Immunotherapy of human immunodeficiency virus infection, TIPS 12:107 (1991).
H. Ishitsuka, Y. Umeda, J. Nakamura and Y. Yagi, Protective activity of thymosin against opportunistic infections in animal models, Cancer Immunol. Immunother. 14:145 (1983).
J. W. Hadden, Thymomimetic drugs, in: “Immunopharmacology,” P. A. Miescher, L. Bolis and M. Ghione, eds., Serono Symposia Publications, Raven Press, New York (1985).
M. Bruley-Rosset, I. Florentin, N. Kiger, J. Shulta and G. Mathe, Restoration of impaired immune functions of aged animals by chronic bestatin treatment, Immunol. 38:75 (1979).
J. M. Lang, J-L. Touraine, C. Trepo, P. Choulet, M. Kirkstetter, A. Falkenrodt, L. Herviou, J. M. Livrozet, G. Retornaz, F. Touraine, G. Renoux, M. Renoux, M. Musset, J. Caraux and AIDS-Imuthiol French Study Group, Randomized, double-blind, placebo-controlled trial of ditiocarb sodium (“Imuthiol”) in human immunodeficiency virus infection, Lancet 24(2) 8613: 702 (1988).
E. M. Hersh, G. Brewton, D. Abrams, J. Bartlett, J. Galpin, G. Parkash, R. Gorter, M. Gottlieb, J. J. Jonikas, S. Landesman, A. Levine, A. Marcel, E. A. Petersen, M. Whiteside, J. Zahradnik, C. Negron, F. Boutitie, J. Caroux, J-M. Dupuy and L. R. Salmi, Ditiocarb sodium (Diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS, JAMA 265:1538 (1991).
J. G. Bekesi, P. H. Tsang, J. I. Wallace and J. P. Roboz, Immunorestorative properties of isoprinosine in the treatment of patients at high risk of developing ARC or AIDS, J. Clin. Lab. Immunol. 24:155 (1987).
D. Abrams, M. Grieco, M. Gottlieb and M. Speer, eds., AIDS/HIV Experimental Treatment, AMFAR Directory, Vol. 3, No. 1 (1989).
C. Pedersen, E. Sandstrom, C. S. Pedersen, G. Norkrans, J. Gersteft, A. Karlsson, K. C. Christiansen, C. Hakansson, P. Pehrson, J. O. Nielsen, H. J. Jurgenssen and the Scandinavian Isoprene Study Group, The efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection, New Eng. J. of Med. 322:1757 (1990).
C. DeSimone, F. Albertini, M. Almaviva, G. Angarano, F. Chioda, P. Costiglio, S. Delia, A. Ferlini, F. Gritti, G. Mazzarello, F. Milazzo, M. Montioni, P. Marciso, G. Pastore, E. Raise, G. Santini, F. Sorice, A. Terragna, G. Visco and V. Vullo, Clinical and immunological assessment in HIV+ subjects receiving inosine-pranobex: A randomized, multicentric study, Med. Onc. Turn. Pharmacother. 10:299 (1988).
J. W. Hadden, “Advances of Immunopharmacology 4,” J. W. Hadden, F. Spreafico, Y. Yamamura, K. F. Austen, P. Dukor and K. Masek, eds., Pergamon Press, Oxford (1989).
M. I. Luster, D. R. Germolec, K. L. White, B. A. Fuchs, M. M. Fort, J. E. Tomaszewski, M. Thompson, P. C. Blair, J. A. McCay, A. E. Munson and G. J. Rosenthal, A comparison of three nucleoside analogs with anti-retroviral activity on immune and hematopoietic functions in mice: In vitro toxicity to precursor cells and microstromal environment, Toxic. Appl. Pharmacol. 101:328 (1989).
J. W. Hadden, E. M. Hadden, Y. Wang, M. Sosa, R. Coffey and A. Giner-Sorolla, Methyl inosine monophosphate (MIMP)-A new purine immunomodulator, Fifth Int. Conf. on Immunopharmacol., Tampa, Florida, 1991, abstract #107 (in press Int. J. of Immunopharmacol.).
M. Sosa, Y. Wang, A. Saha, T. Wadsworth and J. W. Hadden, Methyl inosine monophosphate (MIMP) promotes immune responses in mice, Ibid, abstract #108.
J.-L. Touraine, K. Sanhadji, O. de Bouteiller and J. W. Hadden, In vitro effects of inosine monophosphate methyl (Me IMP) on human prothymocyte differentiation, Ibid, abstract #109.
M. Sosa, Y. Noso and J. W. Hadden, Methyl inosine monophosphate (MIMP) stimulates macrophage related functions in vitro and in vivo, Ibid, abstract #110.
E. M. Hadden, M. Sosa, M. Strand, R. Coffey and J. W. Hadden, Methyl inosine monophosphate (MIMP) restores depressed lymphoproliferative response of normal human and murine T lymphocytes, Ibid, abstract #111.
J. W. Hadden, J. Ongradi, S. Specter, D. Nelson, E. M. Hadden, M. Sosa, C. Monell and M. Strand, Methyl inosine monophosphate (MIMP) restores HIV-associated suppression of the proliferative responses of human lymphocytes in vitro, Ibid, abstract #112.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer Science+Business Media New York
About this chapter
Cite this chapter
Hadden, J.W. (1992). Recent Thoughts on the Immunotherapy of Infectious Diseases Including HIV Infection. In: Friedman, H., Klein, T.W., Yamaguchi, H. (eds) Microbial Infections. Advances in Experimental Medicine and Biology, vol 319. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3434-1_2
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3434-1_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6519-8
Online ISBN: 978-1-4615-3434-1
eBook Packages: Springer Book Archive